RU2006106228A - Фармацевтическая композиция, используемая для мобилизации стволовых клеток - Google Patents
Фармацевтическая композиция, используемая для мобилизации стволовых клеток Download PDFInfo
- Publication number
- RU2006106228A RU2006106228A RU2006106228/15A RU2006106228A RU2006106228A RU 2006106228 A RU2006106228 A RU 2006106228A RU 2006106228/15 A RU2006106228/15 A RU 2006106228/15A RU 2006106228 A RU2006106228 A RU 2006106228A RU 2006106228 A RU2006106228 A RU 2006106228A
- Authority
- RU
- Russia
- Prior art keywords
- csf
- plgf
- stem cells
- pharmaceutical composition
- combined preparation
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1858—Platelet-derived growth factor [PDGF]
- A61K38/1866—Vascular endothelial growth factor [VEGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/193—Colony stimulating factors [CSF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Zoology (AREA)
- Vascular Medicine (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Diabetes (AREA)
- Surgery (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Claims (10)
1. Комбинированный фармацевтический препарат, содержащий G-CSF и PlGF в качестве активных веществ, используемый для мобилизации стволовых клеток крови у пациента или у нуждающегося в этом субъекта.
2. Комбинированный препарат по п.1, где G-CSF и PlGF вводятся указанному пациенту или субъекту одновременно или раздельно.
3. Комбинированный препарат по п.1 или 2 для парентерального введения.
4. Комбинированный препарат по п.3, содержащий рекомбинантный hG-CSF и rhPlGF.
5. Комбинированный препарат по п. 4, содержащий от 1 до 150 мкг/кг G-CSF и от 10 до 300 мкг/кг PlGF.
6. Применение комбинации G-CSF и PlGF в изготовлении фармацевтической композиции для лечения состояний, нарушений или заболеваний, при которых необходима мобилизация стволовых клеток крови.
7. Применение по п.6 в изготовлении парентеральной композиции.
8. Применение по п.6, где указанные G-CSF и PlGF представляют собой рекомбинантный человеческий G-CSF (rhG-CSF) и рекомбинантный человеческий PlGF (rhPlGF).
9. Применение по п.6, где указанные состояния, нарушения или заболевания включают в себя органную или клеточную трансплантацию и радиохимиотерапию опухолей, в частности, аутологичную или аллогенную трансплантацию стволовых клеток у пациентов с неходжкинской лимфомой (НХЛ), рецидивом ходжкинской лимфомы (ХЛ), множественной миеломой или находящихся на стадии восстановления после миелосупрессивной химиотерапии.
10. Применение по п.6, где фармацевтическая композиция обеспечивает 10 мкг/кг G-CSF и 130 мг/кг PlGF ежедневно.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP03017174 | 2003-07-29 | ||
| EP03017174.8 | 2003-07-29 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2006106228A true RU2006106228A (ru) | 2007-09-10 |
| RU2351357C2 RU2351357C2 (ru) | 2009-04-10 |
Family
ID=34130041
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2006106228/15A RU2351357C2 (ru) | 2003-07-29 | 2004-07-23 | Фармацевтическая композиция, используемая для мобилизации стволовых клеток |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US20070036747A1 (ru) |
| EP (1) | EP1660115B1 (ru) |
| JP (1) | JP4855253B2 (ru) |
| KR (1) | KR101192136B1 (ru) |
| CN (1) | CN100534528C (ru) |
| AT (1) | ATE513555T1 (ru) |
| AU (1) | AU2004262909B2 (ru) |
| BR (1) | BRPI0412989A (ru) |
| CA (1) | CA2526244C (ru) |
| DK (1) | DK1660115T3 (ru) |
| ES (1) | ES2369487T3 (ru) |
| IL (1) | IL173369A (ru) |
| MX (1) | MXPA06000017A (ru) |
| NO (1) | NO20060955L (ru) |
| NZ (1) | NZ543612A (ru) |
| PL (1) | PL1660115T3 (ru) |
| PT (1) | PT1660115E (ru) |
| RU (1) | RU2351357C2 (ru) |
| SI (1) | SI1660115T1 (ru) |
| WO (1) | WO2005014023A1 (ru) |
| ZA (1) | ZA200509361B (ru) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5130453B2 (ja) | 2005-03-02 | 2013-01-30 | ユニバーシティ オブ メリーランド，ボルティモア | 新規なｃ−１７−ヘテロアリールステロイドｃｙｐ１７阻害剤／抗アンドロゲン：合成、インビトロ生物活性、薬物動態および抗腫瘍活性 |
| US20100048524A1 (en) | 2008-03-14 | 2010-02-25 | Angela Brodie | Novel C-17-Heteroaryl Steroidal CYP17 Inhibitors/Antiandrogens;Synthesis In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity |
| US20110118219A1 (en) | 2008-03-25 | 2011-05-19 | University Of Maryland, Baltimore | Novel prodrugs of c-17-heteroaryl steroidal cyp17 inhibitors/antiandrogens: synthesis, in vitro biological activities, pharmacokinetics and antitumor activity |
| US8785423B2 (en) | 2008-04-14 | 2014-07-22 | University Of Maryland, Baltimore | Compositions and methods of inducing endoplasmic reticulum stress response for the treatment of cell proliferative diseases |
| US8791095B2 (en) | 2009-02-05 | 2014-07-29 | Tokai Pharmaceuticals, Inc. | Steroidal CYP17 inhibitors/antiandrogens |
| JP2012516900A (ja) | 2009-02-05 | 2012-07-26 | トーカイ ファーマシューティカルズ，インク． | ステロイド性ｃｙｐ１７阻害剤／抗アンドロゲン剤の新しいプロドラッグ |
| WO2011017534A2 (en) | 2009-08-07 | 2011-02-10 | Tokai Pharmaceuticals, Inc. | Treatment of prostate cancer |
| KR20160023638A (ko) | 2013-02-28 | 2016-03-03 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | 줄기세포를 이동하기 위한 방법 및 조성물 |
| BR112015023098A2 (pt) | 2013-03-14 | 2017-07-18 | Univ Jefferson | agentes de infrarregulação do receptor de andrógeno e usos dos mesmos |
| JP2016528252A (ja) | 2013-08-12 | 2016-09-15 | トーカイ ファーマシューティカルズ， インコーポレイテッド | アンドロゲン標的治療を使用する新生物障害の処置のためのバイオマーカー |
| LT6161B (lt) | 2013-09-27 | 2015-06-25 | Uab Profarma | Granuliocitų kolonijas stimuliuojančio faktoriaus sulieti baltymai su kitais augimo faktoriais, optimaliai su kamieninių ląstelių faktoriumi, ir jų gavimo būdas |
| CN114891746A (zh) * | 2021-12-21 | 2022-08-12 | 青岛今墨堂生物技术有限公司 | 一种犬全血造血干细胞的制备方法 |
| WO2023133595A2 (en) | 2022-01-10 | 2023-07-13 | Sana Biotechnology, Inc. | Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses |
| WO2024081820A1 (en) | 2022-10-13 | 2024-04-18 | Sana Biotechnology, Inc. | Viral particles targeting hematopoietic stem cells |
| WO2024119157A1 (en) | 2022-12-02 | 2024-06-06 | Sana Biotechnology, Inc. | Lipid particles with cofusogens and methods of producing and using the same |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5773252A (en) * | 1995-06-05 | 1998-06-30 | Human Genome Sciences, Inc. | Fibroblast growth factor 15 |
| DE19549232C2 (de) * | 1995-12-20 | 1998-05-20 | Boehringer Mannheim Gmbh | Verwendung von G-CSF in Kombination mit einem Chemotherapeutikum bei der Behandlung von Erkrankungen, die eine periphere Stammzelltransplantation erfordern |
| US7105168B1 (en) * | 2002-06-04 | 2006-09-12 | D. Collen Research Foundation Vzw | Method of improving ischemic muscle function by administering placental growth factor |
| DE10234192B4 (de) * | 2002-07-26 | 2009-11-26 | Epoplus Gmbh Co.Kg | Verwendung von Erythropoetin |
| WO2004070018A2 (en) * | 2003-02-04 | 2004-08-19 | Ludwig Institute For Cancer Research | Vegf-b and pdgf modulation of stem cells |
-
2004
- 2004-07-23 AT AT04763431T patent/ATE513555T1/de active
- 2004-07-23 US US10/565,903 patent/US20070036747A1/en not_active Abandoned
- 2004-07-23 BR BRPI0412989-0A patent/BRPI0412989A/pt not_active IP Right Cessation
- 2004-07-23 ES ES04763431T patent/ES2369487T3/es active Active
- 2004-07-23 KR KR1020057023606A patent/KR101192136B1/ko not_active IP Right Cessation
- 2004-07-23 MX MXPA06000017A patent/MXPA06000017A/es active IP Right Grant
- 2004-07-23 JP JP2006521487A patent/JP4855253B2/ja not_active Expired - Fee Related
- 2004-07-23 EP EP04763431A patent/EP1660115B1/en active Active
- 2004-07-23 PT PT04763431T patent/PT1660115E/pt unknown
- 2004-07-23 NZ NZ543612A patent/NZ543612A/en not_active IP Right Cessation
- 2004-07-23 SI SI200431743T patent/SI1660115T1/sl unknown
- 2004-07-23 PL PL04763431T patent/PL1660115T3/pl unknown
- 2004-07-23 DK DK04763431.6T patent/DK1660115T3/da active
- 2004-07-23 CA CA2526244A patent/CA2526244C/en not_active Expired - Fee Related
- 2004-07-23 ZA ZA200509361A patent/ZA200509361B/en unknown
- 2004-07-23 WO PCT/EP2004/008245 patent/WO2005014023A1/en active Application Filing
- 2004-07-23 RU RU2006106228/15A patent/RU2351357C2/ru not_active IP Right Cessation
- 2004-07-23 CN CNB2004800213159A patent/CN100534528C/zh not_active Expired - Fee Related
- 2004-07-23 AU AU2004262909A patent/AU2004262909B2/en not_active Ceased
-
2006
- 2006-01-26 IL IL173369A patent/IL173369A/en not_active IP Right Cessation
- 2006-02-27 NO NO20060955A patent/NO20060955L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| JP2007500157A (ja) | 2007-01-11 |
| KR101192136B1 (ko) | 2012-10-16 |
| EP1660115B1 (en) | 2011-06-22 |
| RU2351357C2 (ru) | 2009-04-10 |
| NZ543612A (en) | 2008-03-28 |
| AU2004262909A1 (en) | 2005-02-17 |
| PT1660115E (pt) | 2011-08-24 |
| WO2005014023A1 (en) | 2005-02-17 |
| ES2369487T3 (es) | 2011-12-01 |
| JP4855253B2 (ja) | 2012-01-18 |
| ZA200509361B (en) | 2007-03-28 |
| NO20060955L (no) | 2006-02-27 |
| DK1660115T3 (da) | 2011-10-10 |
| MXPA06000017A (es) | 2006-03-21 |
| ATE513555T1 (de) | 2011-07-15 |
| BRPI0412989A (pt) | 2006-10-03 |
| PL1660115T3 (pl) | 2011-11-30 |
| AU2004262909B2 (en) | 2010-07-01 |
| KR20060079753A (ko) | 2006-07-06 |
| US20070036747A1 (en) | 2007-02-15 |
| CN1826134A (zh) | 2006-08-30 |
| IL173369A (en) | 2010-12-30 |
| CA2526244A1 (en) | 2005-02-17 |
| CN100534528C (zh) | 2009-09-02 |
| SI1660115T1 (sl) | 2011-10-28 |
| EP1660115A1 (en) | 2006-05-31 |
| IL173369A0 (en) | 2006-06-11 |
| CA2526244C (en) | 2012-03-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2006106228A (ru) | Фармацевтическая композиция, используемая для мобилизации стволовых клеток | |
| ES2637509T3 (es) | (+)-2-[1-(3-Etoxi-4-metoxifenil)-2-metilsulfoniletil]-4-acetilaminoisoindolin-1,3-diona: métodos de uso y composiciones del mismo | |
| Theiss et al. | Dual stem cell therapy after myocardial infarction acts specifically by enhanced homing via the SDF-1/CXCR4 axis | |
| Demchak et al. | Interleukin-2 and high-dose cisplatin in patients with metastatic melanoma: a pilot study. | |
| US10246462B2 (en) | Chemokine receptor modulators and uses thereof | |
| US20240199620A1 (en) | Chemokine receptor modulators and uses thereof | |
| ES2738658T3 (es) | Composición farmacéutica para inhibir la respuesta inmunitaria a través de la inducción de la diferenciación en células T reguladoras y la promoción de la proliferación de células T reguladoras | |
| KR101723265B1 (ko) | mTOR/STAT3 신호억제제 처리된 면역조절능을 갖는 간엽줄기세포 및 이를 포함하는 면역질환의 예방 또는 치료용 세포치료제 조성물 | |
| RU2009108289A (ru) | Комбинированная терапия | |
| JP2010053135A5 (ru) | ||
| CA2560058A1 (en) | A method for inhibiting cancer cell proliferation or increasing cancer cell apoptosis | |
| UA114521C2 (uk) | Солі і тверді форми (s)-3-(4-((4-морфолінометил)-бензил)оксі)-1-оксоізоіндолін-2-іл)-піперидин-2,6-діону і композиції, які їх включають, і способи їхнього застосування | |
| BR112021021165A2 (pt) | Conjugados anticorpo-fármaco de amatoxina e uso dos mesmos | |
| Gazitt et al. | Improved mobilization of peripheral blood CD34+ cells and dendritic cells by AMD3100 plus granulocyte–colony-stimulating factor in non-Hodgkin's lymphoma patients | |
| WO2006078782A3 (en) | Compositions containing agm cells and methods of use thereof | |
| US11918582B2 (en) | Pyrazole pyrimidine compounds and uses thereof | |
| CN107427545A (zh) | 青黛萃取物及其制备方法 | |
| BR112021006033A2 (pt) | Uso de um inibidor de um transportador da família ent no tratamento de câncer e combinação do mesmo com um antagonista do receptor de adenosina | |
| RU2008152746A (ru) | Лечение ишемических заболеваний с применением эритропоэтина | |
| CN105814072A (zh) | 一种五环三萜结构修饰化合物及其制备方法和应用 | |
| WO2002053700A3 (en) | Isolated molecules comprising epitopes containing sulfated moieties, antibodies to such epitopes, and uses thereof | |
| CROWN et al. | Rapid delivery of multiple high-dose chemotherapy courses with granulocyte colony-stimulating factor and peripheral blood-derived hematopoietic progenitor cells | |
| Dodge et al. | Effects of donor vitamin A deficiency and pharmacologic modulation of donor T cell retinoic acid pathway on the severity of experimental graft-versus-host disease | |
| Parr et al. | Allogeneic bone marrow transplantation: procedures and complications | |
| KR20190087359A (ko) | 액상 플라즈마를 이용한 건선의 예방 또는 치료 방법 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | The patent is invalid due to non-payment of fees |
Effective date: 20150724 |